Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Taltirelin

Name: Taltirelin
Brand: TargetMol
SKU: T7590
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T7590Cas No. 103300-74-9

Alias TA-0910

Taltirelin (TA-0910) is at thyrotropin-releasing hormone receptor (TRH-R) superagonist (IC50 of 910 nM and EC50 of 36 nM for stimulating an increase in cytosolic Ca2+ concentration (Ca2+ release))[1].

Taltirelin

Copy Product Info

😃Good

Catalog No. T7590Alias TA-0910Cas No. 103300-74-9

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
2 mg	$59	5 days	5 days

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	Taltirelin (TA-0910) is at thyrotropin-releasing hormone receptor (TRH-R) superagonist (IC50 of 910 nM and EC50 of 36 nM for stimulating an increase in cytosolic Ca2+ concentration (Ca2+ release))[1].
Targets&IC50	TRHR:910 nM (IC50)
In vivo	Taltirelin (TAL), in mouse models of CRF.?To model fatigue, we used a mouse model of chemotherapy, a mouse model of radiation therapy, and mice bearing colon 26 carcinoma tumors.?We used the treadmill fatigue test to assess fatigue-like behavior after treatment with TAL.?Additionally, we used wild-type and TRH receptor knockout mice to determine which TRH receptor was necessary for the actions of TAL.?Tumor-bearing mice displayed muscle wasting and all models caused fatigue-like behavior, with mice running a shorter distance in the treadmill fatigue test than controls.?TAL reversed fatigue-like behavior in all three models and the mouse TRH1 receptor was necessary for the effects of TAL.?These data suggest that TAL may be useful in alleviating fatigue in all cancer patients and provide further support for evaluating TAL as a potential therapy for CRF in humans[1].
Synonyms	TA-0910

Chemical Properties

Molecular Weight	405.41
Formula	C₁₇H₂₃N₇O₅
Cas No.	103300-74-9
Smiles	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(N)=O
Relative Density.	1.447 g/cm3

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 30 mg/mL (74 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.93 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4666 mL	12.3332 mL	24.6664 mL	123.3319 mL
5 mM	0.4933 mL	2.4666 mL	4.9333 mL	24.6664 mL
10 mM	0.2467 mL	1.2333 mL	2.4666 mL	12.3332 mL
20 mM	0.1233 mL	0.6167 mL	1.2333 mL	6.1666 mL
50 mM	0.0493 mL	0.2467 mL	0.4933 mL	2.4666 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc